Tri Locum Partners LP — 13F Holdings & Portfolio

CIK 1826434 · latest 13F-HR filed 2026-05-18

Tri Locum Partners LP manages $712.5M in 13F-reported U.S. long-equity assets across 17 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are JNJ (14.22%), ISRG (9.91%), TMO (9.13%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 6 new positions, exited 4, added to 2, and trimmed 7.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$712.5M

Long-equity book

Holdings

17

Distinct positions

Period

2026-03-31

Filed 2026-05-18

Q/Q Activity

+6 / −4 / ↑2 / ↓7

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • DEXCOM INC$15.9M +56.7%
  • MADRIGAL PHARMACEUTICALS INC$4.0M +7.9%
Show all 2

Top Trims

  • AXSOME THERAPEUTICS INC.-$26.3M -71.5%
  • JOHNSON & JOHNSON-$23.5M -18.8%
  • UNITED THERAPEUTICS CORP DEL-$17.2M -29.2%
  • TEVA PHARMACEUTICAL INDS LTD-$14.1M -31.4%
  • DIANTHUS THERAPEUTICS INC-$13.4M -52.4%
Show all 7

New Positions

  • INTUITIVE SURGICAL INC$70.6M
  • THERMO FISHER SCIENTIFIC INC$65.1M
  • VERTEX PHARMACEUTICALS INC$57.7M
  • JAZZ PHARMACEUTICALS PLC$30.0M
  • TARSUS PHARMACEUTICALS INC$17.7M
Show all 6

Exited Positions

  • DANAHER CORPORATION$79.4M
  • BOSTON SCIENTIFIC CORP$49.6M
  • IONIS PHARMACEUTICALS INC$44.1M
  • VERA THERAPEUTICS INC$40.8M
Show all 4
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 JOHNSON & JOHNSON JNJ 478160104 $101.3M 14.22% 414,503 SH
2 INTUITIVE SURGICAL INC ISRG 46120E602 $70.6M 9.91% 153,250 SH
3 THERMO FISHER SCIENTIFIC INC TMO 883556102 $65.1M 9.13% 132,413 SH
4 ASCENDIS PHARMA A/S ASND 04351P101 $58.4M 8.20% 255,332 SH
5 VERTEX PHARMACEUTICALS INC VRTX 92532F100 $57.7M 8.10% 129,314 SH
6 ELI LILLY & CO LLY 532457108 $56.8M 7.98% 61,795 SH
7 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $54.1M 7.59% 103,288 SH
8 DEXCOM INC DXCM 252131107 $43.8M 6.15% 698,158 SH
9 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $41.7M 5.86% 70,370 SH
10 NUVALENT INC NUVL 670703107 $31.6M 4.44% 308,506 SH
11 TEVA PHARMACEUTICAL INDS LTD TEVA 881624209 $30.8M 4.32% 1,021,008 SH
12 JAZZ PHARMACEUTICALS PLC JAZZ G50871105 $30.0M 4.21% 158,663 SH
13 ARGENX SE ARGX 04016X101 $23.1M 3.24% 31,635 SH
14 TARSUS PHARMACEUTICALS INC TARS 87650L103 $17.7M 2.49% 252,588 SH
15 DIANTHUS THERAPEUTICS INC DNTH 252828108 $12.2M 1.71% 145,543 SH
16 AXSOME THERAPEUTICS INC. AXSM 05464T104 $10.5M 1.47% 62,116 SH
17 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $7.0M 0.98% 369,588 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-18 $712.5M 17 0001826434-26-000004
2025-12-31 2026-02-17 $770.1M 15 0001826434-26-000002
2025-09-30 2025-11-14 $435.1M 18 0001826434-25-000008